Review of Cornea





Become a fan on Facebook Follow us on Twitter

Rosacea in Full Bloom

Due to ocular rosacea’s chronic nature, it’s a lifelong battle for most patients to maintain corneal health.
Edited by Joseph P. Shovlin, O.D.

8/15/2012

Q: Recently, I saw a patient with severe rosacea-related corneal opacity that is essentially 360° and, at certain areas, is approaching the visual axis. Some marginal thinning is evident, with a marked blepharoconjunctivitis and corneal findings that are apparently refractory (she has seen several doctors). She has tried oral doxycycline and topical steroids, but still has problems. Can you recommend any treatment options?

A: Rosacea is a chronic condition with periods of remission and exacerbations that requires long-term therapy to maintain control. “It is important when dealing with rosacea patients to remember that you can treat the symptoms effectively, but you cannot cure the patient,” says Lloyd Pate, O.D., a clinical associate professor at the University of Houston College of Optometry.

First, examine the patient’s medical records and ask her if any of the prior therapies were successful in controlling her condition while she was using them. Perhaps she only experienced a flare-up after cessation of the therapy.

“It’s not a uniform disease—everybody has a different tolerance to the actual insult, and everybody has a different response to the drugs,” says J. James Thimons, O.D., center director for Ophthalmic Consultants of Connecticut. Each patient will require an individualized treatment plan, which may integrate multiple treatments. Current treatment options include:

Low-dose oral doxycycline. Oracea (Galderma) q.d. is available as a once-daily 40mg capsule, or you can use Periostat (CollaGenex) b.i.d. in a 20mg tablet, also available generically. “Keep the dosage below the therapeutic threshold because the therapy relies on doxycycline’s anti-inflammatory properties, not its antibiotic activity,” Dr. Pate says.




Severe rosacea-related corneal opacity; note the scar and vascularization along the bottom of the patient's eye. Photo: J. James Thimons, O.D.
The drug typically is used in a pulsed fashion—with one month on treatment and one month off.

Azithromycin ointment. Many O.D.s also pulse-dose Azasite (Merck), with one month on and 30 to 45 days off. “The on and off pulsing doesn’t seem to create bacterial resistance,” Dr. Thimons says. “It also gets to the root of the problem—poor meibomium gland function.”

Topical cyclosporine. A clinical trial of 37 patients with rosacea-associated eyelid and corneal changes found that those who used Restasis (Allergan) for three months showed an increase in Schirmer scores, improved mean tear film break-up time and a greater mean reduction in corneal staining scores.1 Another study showed topical cyclosporine is effective in treating ocular rosacea that is unresponsive to standard therapy.2 The majority of responsive patients (71%) were able to discontinue oral medications, but most required long-term maintenance with topical cyclosporine.2

• Topical metronidazole. Studies have suggested that metronidazole 1% gel or 0.75% cream q.d. or b.i.d. also is effective in treating rosacea blepharitis.3

Tea tree oil. “In-office tea tree oil treatment followed by twice-daily lid scrubs with tea tree oil shampoo is a good therapy to consider,” Dr. Pate says.

Intense pulsed light (IPL) therapy. IPL is a newer therapy that has been showing promise in ocular rosacea. Currently, Dr. Thimons is working on a clinical trial in which patients receive IPL treatments once a month for six months, with the goal of improving meibomium gland function. “So far the data looks really good,” he says. “I’d be happy if I had a treatment like this in addition to topical therapy.”

1. Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther. 2009 Jun;26(6):651-9. Epub 2009 Jun 23.
2. Perry HD, Wittpenn JR, D’Aversa G, Donnenfeld ED. Topical cyclosporine 0.05% for the treatment of chronic, active ocular rosacea. Invest Ophthalmol Vis Sci. 2005;46: E-Abstract 2660.
3. Barnhorst DA Jr, Foster JA, Chern KC, Meisler DM. The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology. 1996 Nov;103(11):1880-3.
 




Search on This Topic              
Optometric Retina Society

Optometric Retina Society Newsletter aims to provide clinical updates in retinal disease for primary care optometrists. As part of this mission, the ORS organizes both annual meetings and a quarterly e-newsletter, through which the latest research and clinical findings are presented to attendees and readers.

To subscribe to the Optometric Retina Society quarterly e-newsletter and receive it via e-mail, click here.

Optometric Glaucoma  Society

Optometric Glaucoma Society Newsletter strives to promote excellence in the care of patients with glaucoma through professional education and scientific investigation. Its objectives are to promote the education of health care professionals, to promote glaucoma research, to make this information accessible to health care professionals and the public, and to establish collaboration with other professional organizations.

To subscribe to the E-Journal of the Optometric Glaucoma Society and receive it via e-mail, click here.

Optometric Glaucoma  Society

Optometric Physician Newsletter is a weekly e-journal edited by Art Epstein, O.D. It began in 2001 and discusses current optometric issues, research and industry news.

To subscribe to OP and receive it via e-mail, click here.

Classifieds | Patient Handouts | Optometric Study Center | Editorial Staff | Business Staff | Media Kit | Contact | Privacy Policy | Subscribe